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REVIEW
Physiologic Responses to Hypoxia and Implications for
Hypoxia-Inducible Factors in the
Pathogenesis of Rheumatoid Arthritis
Jo¨rg H. W. Distler,1 Roland H. Wenger,2 Max Gassmann,3 Mariola Kurowska,1 Astrid Hirth,1
Steffen Gay,1 and Oliver Distler1
Introduction
Oxygen homeostasis represents a basic principle
for all higher organisms. Reduction of the normal oxy-
gen concentrations causes a metabolic demise, because
in mitochondrial oxidative phosphorylation, oxygen is
the terminal electron acceptor during ATP formation. In
addition, several enzymatic reactions require oxygen as a
substrate. In contrast, increased oxygen concentrations
bear the risk of oxidative damage to proteins, lipids, and
nucleic acids. Therefore, even slight changes in systemic
and cellular oxygen concentrations induce a tightly reg-
ulated machinery of short- and long-acting response
pathways, aiming to keep the supply of oxygen within the
physiologic range.
In particular, the molecular responses to hypoxia
have been elucidated in detail during the past several years.
In this context, the cloning and molecular characterization
of the transcription factor hypoxia-inducible factor 1
(HIF-1) mark a breakthrough discovery in knowledge of
cellular adaptation to reduced oxygenation (1). Under
hypoxic conditions, HIF-1 protein accumulates in many
different cell types and activates the transcription of genes
that are of fundamental importance for oxygen homeosta-
sis, including genes involved in energy metabolism, angio-
genesis, vasomotor control, apoptosis, proliferation, and
matrix production (2) (Table 1).
However, regulatory mechanisms that are impor-
tant under physiologic conditions may have disastrous
effects when the delicate control of HIF-1 expression is
disrupted in pathologic situations. For example, HIF-1 is
expressed in a variety of tumors and is thought to be a
critical factor in tumor progression (3), because tumor
growth is strongly dependent on blood supply. Indeed, it
has been demonstrated that HIF-1–induced overexpres-
sion of vascular endothelial growth factor (VEGF)
drives the initiation of angiogenesis in many solid tu-
mors. When HIF-1–mediated transcription was dis-
rupted in tumor cells, hypoxia-inducible gene expression
(including that of VEGF) was found to be attenuated,
and vessel density as well as tumor growth were remark-
ably reduced compared with that in control tumor cells
(4,5).
The present review summarizes current knowl-
edge of the molecular signaling pathways in response to
hypoxia. Furthermore, possible links between HIF-1
signaling and the pathogenesis of rheumatoid arthritis
(RA) will be discussed.
Molecular structure of HIF-1
In 1995, Wang et al cloned the transcription
factor HIF-1, based on its ability to bind to the 3
enhancer region of the erythropoietin gene (1). Struc-
tural analysis revealed that HIF-1 consists of 2 different
subunits, HIF-1 (120 kd) and HIF-1 (91–94 kd).
Sequence analyses showed that HIF-1 was a novel
protein, whereas HIF-1 was identical to the dioxin
receptor aryl hydrocarbon receptor nuclear translocator
(ARNT). Both subunits contain a basic helix–loop–helix
domain, enabling them to recognize and bind to specific
DNA sequences, the so-called HIF-1 DNA binding site
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(HBS), within the regulatory regions of hypoxia-
inducible genes. Another characteristic feature of both
proteins are the PAS regions, which are located at the
N-termini and consist of 2 subunits (PAS-A and PAS-B).
PAS is an acronym for the first transcription factors in
which a PAS domain was identified (Per, Arnt, and
Sim). Using HIF-1 deletion mutants, Jiang et al dem-
onstrated that the helix–loop–helix domain and the
PAS-A region of HIF-1 are sufficient for heterodimer-
ization with ARNT (6).
The most intriguing structural element of HIF-1
is the oxygen-dependent degradation (ODD) domain,
which links HIF-1 to the cellular oxygen sensor. This
domain is essential for degradation under normoxic
conditions and for stabilization under hypoxic condi-
tions. HIF-1–induced gene expression is mediated via 2
transactivation domains: one is located at the
C-terminus of HIF-1, whereas the second one overlaps
with the ODD domain. Regulation of the second trans-
activation domain likely occurs as a side effect of the
stabilization of HIF-1, whereas the C-terminal transac-
tivation domain is functionally independent from the
ODD domain (for review, see refs. 7–9). The structural
elements of HIF-1 are shown in Figure 1.
Stabilization of HIF-1 protein
Whereas the concentration of HIF-1/ARNT is
independent of oxygen levels, cellular HIF-1 is not
detectable under normoxic conditions, because HIF-1
is degraded in proteasomes immediately after transla-
tion (Figure 2). The levels of HIF-1 increase exponen-
tially after exposure to an oxygen concentration of6%,
with a cell-type–dependent maximal response at a con-
centration of 0.5%. This corresponds to a partial
pressure of O2 of 10–15 mm Hg. In contrast, stress-
inducible transcription factors such as activator protein 1
(AP-1) and nuclear factor B are induced only at
near-anoxic oxygen levels (10,11).
The molecular basis for this oxygen-dependent
regulation is hydroxylation of two proline residues at
positions 402 and 564 within the ODD domain of
HIF-1 (12), which is similar to the prolyl modification
of collagens (13,14). A family of 4 HIF prolyl hydroxy-
lase domains (PHDs), designated PHD-containing pro-
teins, has been identified so far, based on their similarity
to the Caenorhabditis elegans homolog EGL-9 and col-
lagen hydroxylases (15–17). The PHDs are iron-
dependent dioxygenases requiring oxygen and oxogluta-
rate as co-substrates. Binding of oxygen requires vitamin
C–dependent maintenance of the iron in the catalytic
site as a ferrous ion. PHDs use one of the bound oxygen
atoms to hydroxylate proline residues 402 or 564 of
HIF-1, whereas the second oxygen atom is incorpo-
rated into oxoglutarate, thereby generating succinate
and carbon dioxide. The ability of PHDs to modify
HIF-1 is limited by the oxygen concentration. Under
normoxic conditions, PHDs can hydroxylate HIF-1
efficiently, leading to the rapid degradation of the
HIF-1 subunit, whereas low oxygen levels prevent this
reaction. Therefore, members of the PHD family func-
tion as an intracellular oxygen–sensing mechanism and
provide the molecular basis for the regulation of HIF-1
protein concentrations by cellular oxygen partial pres-
sure (16).
Table 1. Genes regulated by hypoxia-inducible factor 1 at the
transcription level*
Functional group/gene product Ref.
Anaerobic metabolism 64
Hexokinases 1 and 2 64, 119, 120
Phosphofructokinase L 64, 120
Aldolase C 64
Triosephosphate isomerase 64, 120
Pyruvate kinase M 64, 120
Lactate dehydrogenase A 64
Enolase 1 33, 64
Glucose transporter 1
pH regulation
Carbonic anhydrase IX 121
Nucleotide metabolism
Adenylate kinase 3 33
Angiogenesis
VEGF- and endocrine gland–derived VEGF 64, 199, 122, 123
VEGF receptor 1 (Flt-1) 124
Plasminogen activator inhibitor 1 63
Vascular tonus
1B-adrenoreceptor 125
Inducible nitric oxide synthase 2 126
Endothelin 1 26, 127
Heme oxygenase 1 128
Erythropoiesis
Erythropoietin 129–131
Proliferation and apoptosis
p21 119
Nip3 (BNIP3) 132, 133
Nip3-like protein X 133
Insulin-like growth factor 2 30
Insulin-like growth factor binding proteins 1, 2, 3 30, 134
Iron metabolism
Transferrin 32
Transferrin receptor 135
Ceruloplasmin 136
Matrix metabolism
Prolyl 4-hydroxylase (I) 137
Collagen type V (I) 121
Transcription factors
Dec-1 121
Ets-1 130
* VEGF  vascular endothelial growth factor.
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Recently, an additional mechanism for the regu-
lation of HIF-1 protein stability was identified (18).
Using pull-down assays and deletion constructs, Jeong et
al demonstrated that an ADP-ribosylation factor domain
protein (ARD1) homolog binds directly to the ODD
domain of HIF-1 in the cytoplasm. After binding,
ARD1 acetylates a single lysine residue at position 532
in the ODD domain. In vitro ubiquitination assays
revealed that only acetylation of lysine 532 (but not
other lysine residues) stimulates the rapid degradation
of HIF-1. Mutation of lysine residue 532 or application
of antisense ARD1 resulted in stabilization of HIF-1
even under normoxic conditions. The role of ARD1-
dependent acetylation was further confirmed by experi-
ments showing that inhibition of deacetylation with
sodium butyrate or trichostatin A markedly reduced the
accumulation of HIF-1 under hypoxic conditions. As
shown by VEGF promoter–driven luciferase reporter
gene assays, ARD1 not only destabilizes HIF-1 protein
but also down-regulates the transactivation activity of
HIF-1 in ARD1-transfected HT1080 cells exposed to
hypoxic conditions.
Blockade of hydroxylation of proline residues 402
and 564 as well as blockade of acetylation of lysine 532
have convincingly been demonstrated to prevent degra-
dation of HIF-1 under normoxic conditions, thus abol-
ishing the oxygen-dependent regulation of HIF-1 sig-
naling (13,18,19). These findings suggest that both
pathways are essential for the physiologic regulation of
the cellular responses to hypoxia. However, many ques-
tions have not yet been addressed sufficiently. For
instance, it is currently unclear whether the PHD iso-
forms are functionally redundant and whether other
family members might compensate for the loss of one
PHD. Experiments in vitro suggest that PHD2 has the
highest specific affinity for HIF-1 (20), but the rele-
vance of this finding for the degradation of HIF-1 in
specific tissues in vivo is not clear. Moreover, regulation
of the expression of PHDs and ARD1 has not been
clarified. Interestingly, preliminary data indicate that
some members of the PHD family might be induced by
hypoxia itself (16). Further studies are needed to show
whether differential expression and/or mutations of
these enzymes are linked to certain disease manifesta-
tions in vivo.
The rapid degradation of HIF-1 under nor-
moxic conditions is mediated by the von Hippel-Lindau
(VHL) tumor suppressor gene product pVHL (21). The
 subunit of pVHL interacts directly with the ODD
domain of HIF-1 if proline residues 402 and 564 are
hydroxylated, but not without this modification (Figure
2). The VHL protein itself is part of the E3 ubiquitin
ligase complex consisting of elongin B and C, Cul-2,
Rbx1, E2, and several other incompletely characterized
Figure 1. Structural elements of hypoxia-inducible factor 1 (HIF-1). The basic helix–loop–helix (HLH)
domain is essential for DNA binding of HIF-1. The 2 PAS (Per, Arnt, and Sim) domains of HIF-1 are involved
in heterodimerization and DNA binding and might also influence transactivation. HIF-1 bears 2 transactivation
domains (TADs), one at the C-terminus and one within the oxygen-dependent degradation (ODD) domain. The
ODD domain mediates degradation of HIF-1 under normoxic conditions. Hydroxylation (OH) of proline
residues 402 and 564 within the ODD domain of human HIF-1 by prolyl hydroxylases under normoxic
conditions promotes binding of the von Hippel-Lindau protein and degradation of HIF-1; hydroxylation of
asparagine residue 803 in the C-terminal transactivation domain at normoxic PO2 levels decreases the
transactivation of HIF-1–regulated genes. Similar to hydroxylation of proline residues 402 and 564, acetylation
(Ac) of lysine residue 532 by ADP-ribosylation factor domain protein 1 leads to degradation of HIF-1 under
normoxic conditions. Phosphorylation (P) of unidentified residues has also been shown to regulate transactiva-
tion activity of HIF-1.
12 DISTLER ET AL
components. Interaction of proline-hydroxylated HIF-1
and pVHL/E3 ubiquitin ligase complex activates the
ubiquitination machinery, thereby promoting a signal
for the degradation of HIF-1 within the proteasome
(13,19). A similar mechanism of recognition is proposed
for the acetylated lysine residue 532, because this mod-
ification has also been shown to stimulate ubiquitination
of HIF-1 (18). Under hypoxic conditions, the ODD
domain of HIF-1 is not hydroxylated or acetylated,
pVHL cannot bind, and subsequently HIF-1 is not
ubiquitinated. This inhibits degradation of HIF-1 in the
proteasome, leading to stabilization of the HIF-1 pro-
tein.
Nuclear translocation of HIF-1
Using an HIF–green fluorescent protein (GFP)
fusion protein, Kallio et al observed that HIF-1 is
translocated into the nucleus at low oxygen concentra-
tions, with a complete nuclear import after 1 hour of
hypoxic exposure at 37°C (22). As with other transcrip-
tion factors, the nuclear import of proteins larger than
45 kd is an energy-dependent transport process that
requires the presence of nuclear localization signals
(NLS) within the transported transcription factor. The
HIF-1 protein contains 2 NLS motifs, one within the
basic helix–loop–helix domain at the N-terminus and a
second one at the C-terminus. Transfection of COS-7
cells with different GFP–HIF-1 fusion proteins showed
that the C-terminal (but not the N-terminal) NLS motif
mediates the hypoxia-inducible nuclear import of HIF-
1, and that the B unit of the PAS domain is involved in
the repression of the nuclear import of HIF-1 under
normoxic conditions (22). Subsequent analysis revealed
that the C-terminal NLS motif of HIF-1 represents a
Figure 2. Schematic overview of the regulation and action of HIF-1. Under normoxic conditions, HIF-1 is
rapidly degraded. Hydroxylation of proline residues and acetylation of a lysine residue lead to binding of the von
Hippel-Lindau protein (pVHL) as part of the E3 ubiquitin ligase complex. Subsequently, the HIF-1 protein
undergoes ubiquitination (Ub) and rapid degradation in proteasomes. Under hypoxic conditions, hydroxylation
and acetylation do not occur due to the lack of oxygen, the von Hippel-Lindau/E3 ubiquitin ligase complex cannot
bind, and the HIF-1 protein is stabilized. Then, HIF-1 is translocated into the nucleus, dimerizes with
HIF-1/aryl hydrocarbon receptor nuclear translocator (ARNT), and recruits cofactors such as cAMP response
element binding protein binding protein (CBP)/p300. Finally, HIF-1 binds to the hypoxia-responsive element
(HRE) in regulatory regions of oxygen-regulated genes and increases their transcription. bHLH  basic
helix–loop–helix (see Figure 1 for other definitions).
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novel form of a bipartite NLS consisting of 2 basic
residues and a spacer of 27 amino acids in between (23).
Despite its name implying a function in nuclear translo-
cation of HIF-1 protein, the “nuclear translocator”
ARNT is not required for this process (24). Interest-
ingly, normoxic overexpression of HIF-1 via a Tet-Off
Expression System (BD Biosciences, San Jose, CA)
leads to an accumulation in the nucleus, suggesting that
the translocation of HIF-1 into the nucleus is blocked
under normoxic conditions by a saturable mechanism
rather than stimulated by hypoxia (25). However, the
molecular mechanisms responsible for this phenomenon
remain unidentified.
Binding of HIF-1 to HIF binding sites, and formation
of the transcriptional complex
After translocation into the nucleus, HIF-1
dimerizes with ARNT/HIF-1 (Figure 2). The HIF-1
heterodimer then binds via the basic helix–loop–helix
domain to the HBS, which as been characterized as a
5-RCGTG-3 motif within the hypoxia-responsive ele-
ment of most hypoxia-regulated genes (8,9,26). The
HBS contains a CpG island, which is well known as a
target for methylation. Indeed, methylation of the CpG
island within the HBS has also been demonstrated for
hypoxia-regulated genes such as erythropoietin, leading
to an abrogation of HIF-1 binding and gene activation
(27). The HBS is essential, but is not sufficient for gene
activation by HIF-1. A complete hypoxia-responsive
element contains, besides the HBS, additional binding
sites for transcription factors that are not sensitive to
hypoxia. These costimulatory factors, including, for ex-
ample, activating transcription factor 1/cAMP response
element binding protein 1 (CREB-1) in the lactate
dehydrogenase A gene (28) or AP-1 in the VEGF gene
(29), are also required for efficient activation of the
transcription of oxygen-sensitive genes. Alternatively,
multimerization of HBS can substitute for additional
transcription factors in several HIF-regulated genes such
as transferrin, phosphoglycerate kinase 1, insulin-like
growth factor binding protein 1, and glucose transporter
1 (30–33).
Regulation of HIF-1 transactivation
For efficient induction of HIF-1–regulated genes,
HIF-1 needs to be activated. Simple blockade of the
degradation of HIF-1 (e.g., with chemical proteasome
inhibitors such as N-carbobenzoxyl-L-leucinyl-L-leucinyl-
L-norvalinal) results in an accumulation of HIF-1 but is
not sufficient for transactivation (34). Two modifications
of HIF-1 involved in the regulation of its activity have
been identified so far, namely, hydroxylation of the
C-terminal transactivation domain (Figure 1) and pro-
tein phosphorylation after activation of tyrosine kinase
receptors (Figure 3).
At low concentrations of oxygen, but not under
normoxic conditions, the C-terminal transactivation do-
main of HIF-1 recruits several coactivators that are
required for HIF-1 signaling (5,35). Mass spectrometry
revealed that under normoxic conditions the molecular
mass of this transactivation domain was 16 daltons
greater than under hypoxic conditions (36). Further
experiments showed that the increase of molecular mass
under normoxic conditions was caused by hydroxylation
of a conserved asparagine residue at position 803 in the
C-terminal transactivation domain (Figure 1). Mutation
of this asparagine residue as well as the lack of hydroxy-
lation lead to a permanent recruitment of cofactors and
yield a constitutively active HIF-1. The enzyme respon-
sible for asparagine hydroxylation has recently been
shown to be identical to factor-inhibiting HIF-1 (FIH-1)
(36–38). FIH-1 forms ternary complexes with HIF-1
and pVHL, which activate histone deacetylases and
hence might counterbalance the changes in the chroma-
tin structure induced by the transcriptional coactivators
p160/steroid receptor coactivator 1 (SRC-1) and cAMP
response element binding protein binding protein
(CBP)/p300. Similar to prolyl hydroxylation within the
ODD domain, iron and oxoglutarate are essential for
asparagine hydroxylation, and this process is limited by
the oxygen partial pressure. Therefore, one might spec-
ulate that FIH-1 is part of the O2-sensing mechanism
(39).
Besides hypoxia, a variety of cytokines and
growth factors have been demonstrated to be capable of
stabilizing and activating HIF-1 under normoxic con-
ditions (Figure 2), at least in cell cultures in vitro.
Examples include interleukin-1 (IL-1), tumor necro-
sis factor  (TNF), transforming growth factor 
(TGF), platelet-derived growth factor, fibroblast
growth factor 2, and insulin-like growth factors (40–42).
Binding of these ligands to their receptor tyrosine
kinases activates, among others, the phosphatidylinositol
3-kinase (PI 3-kinase)/Akt kinase/FK 506 binding pro-
tein 12-rapamycin associated protein (FRAP) pathway.
Stimulation of different receptor tyrosine kinases in
different cell types has been demonstrated to increase
the levels of HIF-1 and induce the transcription of
oxygen-dependent genes (43). This effect could be in-
hibited by antagonists of PI 3-kinase and FRAP. Sur-
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prisingly, the accumulation of HIF-1 upon stimulation
of the PI 3-kinase/Akt kinase/FRAP pathway is caused
by up-regulation of protein synthesis rather than de-
creased proteasomal degradation of HIF-1 mediated
by sequences in the 5-untranslated region of the HIF-1
gene (43). Signaling via the PI 3-kinase/Akt kinase/
FRAP pathway is counterregulated by the tumor sup-
pressor gene PTEN. PTEN protein dephosphorylates
the products of PI 3-kinase reactions. Along this line,
loss of PTEN in tumors leads to a dramatic increase of
HIF-1 protein associated with neoangiogenesis and
tumor progression (44). Most interesting is the fact that
in RA a lack of PTEN is found at sites of synovial
invasion into the cartilage (45).
Cytokines and growth factors can influence the
transcriptional activity of HIF-1 also via the mitogen-
Figure 3. Protein phosphorylation (P) after activation of receptor tyrosine kinases (RTKs). Many growth factors
and cytokines such as interleukin-1, tumor necrosis factor , transforming growth factor (GF) , platelet-
derived growth factor, fibroblast growth factor 2, and insulin-like growth factors can stimulate the transcription
of HIF-1–regulated genes under normoxic conditions. Binding of these cytokines to their cell surface receptors
induces homodimerization of the receptors and activates their tyrosine kinases. One of the intracellular signaling
pathways that is activated by RTKs is the phosphatidylinositol 3-kinase (PI3K; PI 3-kinase)/Akt kinase/FK 506
binding protein 12-rapamycin associated protein (FRAP) pathway. Activation of RTKs stimulates PI 3-kinase,
which in turn phosphorylates Akt (also termed protein kinase B). Akt activates FRAP, leading to an increased
translation of HIF-1 that is sufficient to induce transcription of HIF-1–regulated genes, even under normoxic
conditions. The PI 3-kinase/Akt kinase/FRAP pathway is negatively regulated by the tumor suppressor gene
PTEN. PTEN encodes for a phosphatase that dephosporylates PI phosphates and thus abolishes activation of Akt
and other targets of the PI 3-kinase pathway. Another pathway involved in the regulation of HIF-1 signaling that
is activated upon stimulation with growth factors is the MAP kinase (MAPK) pathway. RTKs recruit the inactive
cytoplasmic Raf protein to the plasma membrane, where it gets fully activated by phosphorylation and
interactions with cationic lipids. Then, Raf binds and phosphorylates mitogen-activated extracellular signal–
regulated kinase (MEK). Finally, MEKs activate the MAPKs p42 and p44 (Erk2 and Erk1), which phosphorylate
HIF-1. This enhances the transcriptional activity of HIF-1 and increases expression of HIF-1–regulated
genes. The PI 3-kinase/Akt/FRAP pathway as well as the MAPK pathway can also be stimulated by Ras.
Stimulated RTKs can activate the small guanosinetriphosphate (GTP) binding protein Ras via the adaptor
molecule Grb2 and the guanine exchange factor mSos. See Figure 1 for other definitions.
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activated protein kinase (MAPK) pathway. Upon acti-
vation of receptor tyrosine kinases, the serine/threonine
protein kinase Raf is activated either by direct phos-
phorylation or via Ras. Raf activates the mitogen-
activated extracellular signal–regulated kinase, which in
turn phosphorylates the MAPKs (46). Members of the
MAPK family such as p42, p44, p38, and p38 can
phosphorylate unidentified residues of HIF-1 in vitro
(Figure 1), leading to electrophoretic migration proper-
ties similar to the modifications of HIF-1 under hy-
poxic conditions (47,48). Phosphorylation of HIF-1 by
MAPKs increases HIF-1–dependent reporter gene ex-
pression, but in contrast to PI 3-kinase/Akt kinase/
FRAP signaling, it does not induce translation of
HIF-1 protein (49).
Cofactors of HIF-1 and negative feedback pathways
For the induction of oxygen-dependent genes by
HIF-1, binding of general coactivators to the 2 trans-
activation domains of HIF-1 is required (50,51). This
includes members of the p300/CBP and p160/SRC-1
family of coactivators, which bear histone acetyltrans-
ferase activity and can remodel the chromatin structure
(52). As described in the previous section, hydroxylation
of asparagine residue 803 of HIF-1 inhibits binding of
the cysteine/histidine-rich domain 1 (CH1) of p300/CBP
to the C-terminal transactivation domain (53). Binding
of the transcription factor p35srj (previously named
melanocyte-specific gene related gene 1 and CITED2)
to the CH1 domain of p300/CBP also prevents the
interaction of p300/CBP with HIF-1 (53). Interestingly,
p35srj is, by itself, a HIF-1 target gene induced by
hypoxia, thereby creating a negative feedback loop.
Finally, an HIF-1 proteasome-targeting factor (HPTF)
was proposed by Berra et al (49), who observed that the
half-life of HIF-1 protein after reoxygenation was
inversely related to the duration of hypoxic exposure,
and that this phenomenon was blocked by inhibition of
HIF-1–dependent transcription. Based on these find-
ings, the authors suggested that HIF-1 induces the
synthesis of HPTF, which in turn activates the HIF-1
degradation pathway after reoxygenation. However, the
molecular structure of HPTF has not been identified.
Because the expression of PHDs might be induced by
hypoxia, further studies must analyze whether HPTF
might be identical to PHD family members.
Other members of the HIF family
Two proteins closely related to HIF-1 have been
identified and designated HIF-2 (54,55) and HIF-3
(56,57). HIF-2 is also referred to as endothelial PAS
domain protein 1 (58), HIF-–like factor (54), and
HIF-related factor (55). HIF-1 and HIF-2 are ubiq-
uitously expressed, whereas HIF-3 shows a more re-
stricted pattern, with high expression levels in the brain,
thymus, and muscle (57,59,60). HIF-2 is similar to
HIF-1 with regard to genomic organization, protein
structure, dimerization with ARNT, DNA binding, and
transactivation (21,35,61,62). Furthermore, the expres-
sion patterns of HIF-1 and HIF-2 are partially over-
lapping, and an accumulation of both proteins can be
observed under hypoxic conditions (59,60,63). There-
fore, one might speculate that one  subunit could
compensate for loss of the other one. However, experi-
ments with knockout mice demonstrated that HIF-
subunits are not functionally redundant, because target-
ing of either one of the HIF- subunits results in
embryonic lethality, and one subunit cannot compensate
for the loss of the other subunit (31,64,65).
Recently, a novel splicing variant of HIF-3,
which inhibits HIF-mediated gene expression, was dis-
covered (66). This antagonist, called the inhibitory PAS
domain protein (IPAS), shows high structural similarity
to the basic helix–loop–helix domain and to a lesser
extent to the PAS region of HIF-1 and HIF-1, which
are necessary for dimerization. However, IPAS lacks the
C-terminal region of HIF-1 and HIF-1, which harbors
the transactivation domains. IPAS is expressed at high
levels in corneal epithelium cells, where it competes with
HIF-1/ARNT to form complexes with HIF-1. Be-
cause the IPAS/HIF-1 complex does not bind to HIF-1
DNA binding sites and does lack transactivation activity,
the overexpression of IPAS prevents HIF-1–mediated
neoangiogenesis in the cornea. Application of IPAS
antisense oligonucleotides to the cornea, a physiologi-
cally hypoxic tissue, induced angiogenesis via an up-
regulation of VEGF by HIF-1. Similarly, stable overex-
pression of IPAS in hepatoma cells inhibited tumor
growth due to a reduced vascular density (66).
Three other inhibitors of HIF-1 have been dis-
covered, but their physiologic relevance is less clear.
Chun et al detected 2 alternative splicing variants of
HIF-1messenger RNA (mRNA) in 293T cells: the first
one, lacking exon 12, is induced by zinc and was there-
fore designated HIF-1Z (67). In the other isoform,
HIF-1516, which is constitutively expressed in 293T
cells, exons 11 and 12 are missing (68). Both of the
resulting proteins are unable to induce transcription of
HIF-1–regulated genes, but they are still able to com-
pete with HIF-1 for dimerization with ARNT and
DNA binding sites. Furthermore, a natural antisense
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transcript, complementary to the 3-untranslated region
of HIF-1 mRNA, was reported (69).
Lessons from knockout experiments: physiologic
functions of HIFs
To further analyze the physiologic functions of
HIFs, gene targeting of HIF-1 and HIF-2 has been
employed. Mice containing one wild-type and one mu-
tant allele for HIF-1 show no morphologic defects,
develop normally, and their acute responses to hypoxia
are also normal (70,71). However, the mechanisms for
adaptation to chronic hypoxia are impaired, with de-
layed development of polycythemia and impaired
hypoxia-induced vascular remodeling with reduced pul-
monary hypertension and reduced right ventricular hy-
pertrophy. Neuronal cells from the carotid body, a major
hypoxia sensory organ, showed reduced activity at low
oxygen levels (70,71).
Mice lacking both alleles for HIF-1 are not
viable and die at mid gestation (approximately embry-
onic day 10.5) (31,64,72). These mice show a wide range
of neuronal malformations, including failure of neural
tube closure, prolapsed neural folds, and cystic enlarge-
ment of the hindbrain, probably due to the profound loss
of supporting mesenchymal cells within these regions. In
addition, cardiovascular defects have been observed in
all HIF-1 knockout embryos. The brachial arch vessels
are either severely hypoplastic or absent, and localized
regions of the dorsal aorta are dilated. The vascular
endothelium is discontinuous and attenuated. Further-
more, abnormal cellular proliferation results in hyper-
plasia of the presumptive myocardium and a subsequent
reduction of the size of the ventricular cavity and of the
outflow tract.
Growth plate chondrocytes in the developing
bone undergo well-controlled phases of cell prolifera-
tion, differentiation, and apoptosis, finally resulting in
the replacement of the cartilage matrix with trabecular
bone matrix. As analyzed by injection with a marker for
bioreductive activity (EF-5), there is a physiologic gra-
dient of oxygenation from the outer to the inner region
of the developing growth plate, which correlates with the
expression of HIF-1 (73). Conditional knockout mice,
lacking HIF-1 specifically in the cartilaginous growth
plate, showed massive cell death in the center of both
the proliferative and hypertrophic zones, leading to
gross skeletal malformation, with shorter hind and fore
limbs. These data indicate that HIF-1 is critical for the
survival of cells in a fully differentiated tissue under
hypoxic conditions. Moreover, epiphyseal chondrocytes
lacking HIF-1 are unable to maintain levels of ATP
under hypoxic conditions, indicating that HIF-1 is
essential for the regulation of chondrocyte metabolism,
probably via an increase in glycolysis. In fact, expression
of extracellular matrix proteins such as aggrecan and
type II collagen is decreased in HIF-1 null chondro-
cytes compared with wild-type chondrocytes (74).
Studies of placentas from ARNT knockout mice
revealed that HIF-1 is also essential for placentation
(75). Under hypoxic conditions, as found in the uterus in
vivo, cultured cytotrophoblasts proliferate, whereas in a
normoxic environment they lose this ability and differ-
entiate (76). Based on experiments with HIF-1 antisense
oligonucleotides in human chorionic villous explants, it
has been suggested that this effect of oxygen tension on
trophoblast differentiation and proliferation is mediated
by TGF3 (77). Similarly, TGF3 induced by HIF-1
prevents scarring in fetal wound healing (78).
Stimuli for HIFs in RA
RA is a chronic inflammatory disease that is
characterized by the formation of a hyperplastic syno-
vium consisting of a variety of cell types, including
synovial fibroblasts, macrophages, as well as B and T
cells. During the course of the disease, the hyperplastic
synovium invades deeply into cartilage and bone, leading
to progressive destruction of the affected joints. Blood
vessels are abundant in the RA synovium, and the total
number of capillaries is increased compared with that in
normal synovium (79). Moreover, morphometric studies
have shown that capillary density appears to be in-
creased in the RA synovium (80). This issue is contro-
versial, however, because, due to an increased distance
between individual cells and the nearest blood vessel in
hyperplastic synovium, the capillary density might ap-
pear to be decreased in certain residues (81,82). In
addition to the possible decrease in vascular density, the
vascular system within RA synovium is less well orga-
nized, thereby disturbing the uniform perfusion of the
tissue. Thus, despite the increase in the absolute number
of vessels in the RA synovium, there is a relative
hypoperfusion and hypoxia, particularly in the lining
layer (80,83). Moreover, the gain of synovial fluid in
affected joints of patients with RA increases the intra-
articular pressure, leading to a further reduction of the
perfusion (84). This effect is obvious in the resting joint
and becomes even more obvious during movement of
the affected joint (85). During exercise, synovial capil-
laries collapse because of the additional increase in
intraarticular pressure. After reopening of the capillar-
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ies, the intraarticular pressure returns to basal levels.
This mechanism not only may lead to a further aggrava-
tion of local hypoxia, but also induces the expression of
proinflammatory mediators in the joint in a hypoxia/
reoxygenation-dependent manner (86).
The presence of reduced oxygen levels in the RA
synovium is further supported by direct measurements
of the oxygen tension and more indirectly by an increase
of hypoxic metabolites in the synovium (87). Analyses of
the oxygen tension in synovial fluid demonstrated that
the mean oxygen levels in patients with RA are reduced
to less than half of those in healthy controls (27 mm Hg
and 63 mm Hg, respectively). Interestingly, the levels of
synovial fluid PO2 correlated with the histologic severity
of the disease, in that patients with severe disease
showed lower levels of PO2 and vice versa (88,89). Direct
measurement of the oxygen tension in the synovium of
RA patients and healthy controls with a polarographic
needle electrode confirmed the reduction of the oxygen
tension in the RA synovium compared with that in
normal synovium (90).
For a variety of cells, glycolysis is the most
important means of generating ATP in the absence of
oxygen, and, in fact, a shift to glycolytic metabolism is a
long-known feature of RA synovium (91). Other mark-
ers of a hypoxic metabolism are also increased in RA
synovium; e.g., levels of lactate as well as acidosis are
enhanced (89).
In addition to hypoxia, a variety of growth factors
and cytokines are up-regulated in RA and are able to
stabilize and activate HIF-1. Included are well-
characterized key players in the pathogenesis of RA
such as IL-1 and TNF. Stimulation of cultured syno-
vial fibroblasts with recombinant IL-1 and TNF in-
creases levels of HIF-1 mRNA. Moreover, incubation
with IL-1 leads to stabilization of HIF-1 (92). Notably,
the impact of other growth factors on HIF-1 has not
been addressed specifically in RA.
HIFs in RA
Despite circumstantial evidence for the presence
of hypoxia in the RA synovium, surprisingly little is
known about the role of the HIF family members in the
pathogenesis of RA. Hollander et al analyzed the ex-
pression of HIF-1 in RA synovium by immunohisto-
chemistry (93). The levels of HIF-1 were strongly
increased in RA samples compared with osteoarthritis
(OA) samples, and no signal was observed in healthy
controls. HIF-1 was expressed in the lining layer and to
a lower extent in the sublining. Staining of serial sections
with anti-CD68 antibodies revealed that HIF-1 was
mainly expressed by synovial macrophages. The up-
regulation of HIF-1 protein in RA synovium compared
with normal synovium was confirmed in another study
(94). However, strong expression of HIF-1 as well as
HIF-2 was also found in synovial specimens obtained
from patients with OA. In addition, HIF-1 and HIF-2
were detected in a variety of cell types, including syno-
vial fibroblasts, macrophages, and endothelial cells (94).
In a recent landmark study (95), Cramer et al
demonstrated that HIF-1 is essential for the initiation
and perpetuation of myeloid cell–mediated inflamma-
tion. Mice with a specific deletion of HIF-1 in myeloid
lineage cells developed less severe disease in different
models of acute and chronic inflammation as compared
with wild-type mice. These included a model for arthri-
tis, in which arthritis is passively induced by transfer of
pooled serum from K/BxN T cell receptor transgenic
mice. Interestingly, these effects were independent of
VEGF, and were attributable to severely reduced glyco-
lysis and energy generation in myeloid cells. Conse-
quently, energy-dependent processes such as intracell-
ular killing of bacterial pathogens, homotypic adhesion,
Matrigel invasion, and motility were significantly im-
paired in HIF-1 knockout macrophages (95).
Interactions between stromal cell–derived factor
1 (SDF-1; CXCL12) and its receptor CXC chemokine
receptor 4 (CXCR4) provide another link between
hypoxia signaling and inflammation. SDF-1 is a chemo-
kine of the CXC family that promotes migration and
activation of CD4 memory cells and other cells express-
ing CXCR4. It was shown recently that SDF-1 was
strongly induced in synovial tissue explants as well as in
cultured synovial fibroblasts under hypoxic conditions,
whereas various inflammatory cytokines such as TGF,
IL-1, and TNF had no effect (96). SDF-1 is expressed
in high levels in the lining layer and in perivascular areas
of the sublining of patients with RA (97,98). In contrast,
SDF-1 is detectable only in single cells in the lining of
OA patients and healthy controls, consistent with the
higher oxygen tension in these joints. In addition, the
percentage of CXCR4-positive CD4 memory cells is
significantly elevated in the RA synovium compared
with that in OA control synovium. Interestingly, almost
all CD4 memory cells in the RA synovium express
CXCR4, although only one-third of peripheral CD4
memory cells from these patients express this receptor.
Therefore, one might speculate that CXCR4-positive
CD4 memory cells migrate along a gradient of SDF-1
into the synovium, suggesting an important role for
hypoxia-induced SDF-1 in the accumulation of memory
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cells in the synovium of RA patients. In a similar
manner, SDF-1 appears also to stimulate the migration
of monocytes into the synovium, as shown with U937
cells in a SCID mouse transplantation model (99). The
importance of the SDF-1/CXCR4 pathway in the patho-
genesis of inflammatory arthritis is emphasized by find-
ings in collagen-induced arthritis in mice (100). Treat-
ment of the mice with AMD3100, a specific antagonist of
CXCR4, between the time of immunization and devel-
opment of the first symptoms of arthritis, reduced
infiltration of leukocytes, hyperplasia of the synovium,
and pannus formation.
The role of VEGF in RA
Angiogenesis has been suggested as a crucial
pathogenic step in early RA (101). Indeed, endothelial
cells in the RA synovium are activated, showing an
increased expression of proliferation markers such as
proliferating cell nuclear antigen and Ki-67 compared
with that in patients with OA and healthy controls (102).
Furthermore, synovial fluids from patients with RA
induce the formation of tubular networks resembling
capillaries in cultured endothelial cells (103). These
findings demonstrate an up-regulation of angiogenesis
in the diseased joint, but the formation of new vessels
fails to keep pace with the rapid thickening of the
synovium, largely caused by hyperplasia through the
influx of macrophages and the impaired apoptosis of RA
synovial fibroblasts. In addition, markers of cell death
are increased in endothelial cells of RA patients, which
suggests increased endothelial cell turnover in the in-
flamed synovium (104). The stimulation of angiogenesis
under hypoxic conditions is part of the long-term re-
sponse in order to reestablish normal tissue oxygen
supply. This situation is similar to that observed in
rapidly growing tumors. The high metabolic demand of
the proliferating tumor cells results in hypoxia, espe-
cially in the inner parts of the tumor, which in turn
stimulates angiogenesis to enhance the supply of nutri-
ents (105).
VEGF is one of the strongest and best character-
ized stimulators of angiogenesis (for review, see refs. 106
and 107). Hypoxia up-regulates levels of VEGF mRNA
by transcriptional activation via HIF-1 and, to a certain
extent, by an increase in mRNA stability. VEGF is
involved in the regulation of different steps of the
angiogenic cascade. As such, VEGF contributes to the
initial vasodilatation by induction of nitric oxide, and
increases the permeability of endothelial cells, but it also
induces synthesis of plasminogen activators and matrix
metalloproteinase 1 in endothelial cells necessary for
remodeling of the perivascular matrix. Furthermore,
VEGF prevents endothelial cells from undergoing apo-
ptosis and stimulates the proliferation and migration of
endothelial cells (16,43). Application of VEGF as a
single factor is able to induce angiogenesis in in vivo
models such as the cornea pocket assay and the cho-
rioallantoic membrane assay.
Levels of VEGF are markedly higher in the
serum as well as the synovial fluid of patients with RA
compared with patients with OA and healthy controls
(108,109). The concentration of VEGF in the serum of
patients with RA correlates well with the levels of
C-reactive protein (110). In addition, there is also a
significant correlation between serum levels of VEGF at
early stages of RA and the development of radiologic
deterioration within 12 months, as analyzed by radio-
graphs scored according to the modified Sharp method
(111). Consistent with these findings, high vascularity
detected by dynamic enhanced magnetic resonance im-
aging or power Doppler ultrasonography is correlated
with increased joint erosion in early RA (112). The
important role of HIF-1/hypoxia-induced VEGF syn-
thesis in the pathogenesis of RA is further supported by
a study in which a soluble form of VEGF receptor 1 was
applied to mice with collagen-induced arthritis (113).
Soluble VEGF receptor 1 functions as an antagonist of
VEGF signaling, and treatment with this molecule sig-
nificantly reduced paw swelling and joint destruction in
this model.
Open questions
Based on our ongoing interest in the effects of
hypoxia in various systems (8–10,25–27,32,77,78,114)
and in particular in the rheumatic diseases (106,107,115–
118), we aimed to discuss notions relevant to RA. In this
regard, these findings outline the possible role of hyp-
oxia and HIF-1 in the pathogenesis and progression of
RA. They might also offer a chance for new, therapeutic
strategies in the treatment of RA. Based on the circum-
stantial evidence for reduced levels of oxygen in the
diseased joints, such strategies include the generation of
“mobile” cells such as monocyte/macrophages, which
are transduced with therapeutic genes under the control
of a hypoxia-inducible enhancer (93). Application of
such cells would then lead to selective expression of the
gene of interest in the hypoxic joints and would thereby
allow targeting of multiple joints at the same time.
However, many problems have to be solved before such
a scenario might become applicable for use in the clinic.
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Genes under the control of a hypoxia-inducible pro-
moter are likely expressed not only locally in the affected
joint after systemic application, but also in a variety of
other physiologically hypoxic tissues, giving way to a
number of unwanted effects (8,9,114). In addition, many
molecular aspects of HIF-1 signaling have not yet been
addressed in RA. For example, to date, downstream
pathways of HIF-1 have not been analyzed systemati-
cally and might include molecules favoring as well as
antagonizing certain pathways of the disease. Other
open questions include whether hypoxia and signaling
via HIFs might contribute to the aggressive and invasive
phenotype of synovial fibroblasts as observed for tumor
metastases, and whether RA synovial fibroblasts might
react differently to hypoxia than do normal fibroblasts or
fibroblasts from other organs. Furthermore, the expres-
sion of HIF-2 and HIF-3 in the joint has not been
investigated. Are they also up-regulated in RA synovium
as has been demonstrated for HIF-1? If so, are there
links for HIF-2 and HIF-3 to the pathogenesis of RA?
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